知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

83 条记录 (耗时 0.031 秒)

    Method and means for reducing device contention by random accessing and partial track staging of records according to a first DASD format but device mapped according to a second DASD format
    1.
    发明授权
    Method and means for reducing device contention by random accessing and partial track staging of records according to a first DASD format but device mapped according to a second DASD format 失效
    用于通过随机访问减少设备争用的方法和装置，以及根据第一DASD格式的记录的部分轨道分段，但是根据第二DASD格式映射的设备

    公开(公告)号：US06470421B1

    公开(公告)日：2002-10-22

    申请号：US09632413

    申请日：2000-08-04

    申请人： Thao B. Bui ,  James C. Chen ,  Chan Y. Ng

    发明人： Thao B. Bui ,  James C. Chen ,  Chan Y. Ng

    IPC分类号： G06F1200

    CPC分类号： G06F3/061 ,  G06F3/0638 ,  G06F3/065 ,  G06F3/0689 ,  G06F12/0866

    摘要： A staging method and means for both device read and update write operations in which messages and commands between a storage subsystem and a fixed-block formatted RAID array emulating a variable-length record (CKD) formatted device for both read and write operations are evaluated to ascertain whether the record addressing was random and truly in record mode. If they are in that mode, then partial track staging by the RAID array control from the fixed-block formatted HDDs to a subsystem cache or the like would reduce device contention by reading and staging less than full track.

    摘要翻译： 用于设备读取和更新写入操作的分段方法和装置，其中存储子系统和固定块格式的RAID阵列之间的消息和命令模拟用于读取和写入操作的可变长度记录（CKD）格式化的设备被评估为 确定记录寻址是否是随机的，真正的记录模式。 如果它们处于该模式，则通过RAID阵列控制从固定块格式的HDD到子系统高速缓存等的部分跟踪分级将通过读取和分期小于全部轨道来减少设备争用。

    Method and means for utilizing device long busy response for resolving detected anomalies at the lowest level in a hierarchical, demand/response storage management subsystem
    3.
    发明授权
    Method and means for utilizing device long busy response for resolving detected anomalies at the lowest level in a hierarchical, demand/response storage management subsystem 失效
    方法和装置，用于利用设备长时间忙响应来解决分级，需求/响应存储管理子系统中最低级别的检测到的异常

    公开(公告)号：US5968182A

    公开(公告)日：1999-10-19

    申请号：US854441

    申请日：1997-05-12

    申请人： James C. Chen ,  Julia Liu ,  Chan Y. Ng ,  William G. Sherman, II

    发明人： James C. Chen ,  Julia Liu ,  Chan Y. Ng ,  William G. Sherman, II

    IPC分类号： G06F11/14 ,  G06F11/00

    CPC分类号： G06F11/1435

    摘要： A method and means within a hierarchical, demand/response DASD subsystem of the passive fault management type in which, upon the occurrence of fault, error, or erasure, a long device busy signal of finite duration is provided to a host CPU. Any DASD storage device subject to the anomaly is isolated from any host inquiry during this interval. These measures permit retry or other recovery procedures to be implemented transparent to the host and the executing application. This avoids premature declarations of faults, errors, or erasures and consequent host application aborts and other catastrophic measures. If the detected anomaly is not resolved within the allotted time, then other data recovery procedures can be invoked including device reset, the status reported to the host, and the next request processed.

    摘要翻译： 在被动故障管理类型的分级，需求/响应DASD子系统中的方法和手段，其中，在发生故障，错误或擦除时，向主机CPU提供有限持续时间的长设备忙信号。 遇到异常的任何DASD存储设备在此间隔期间与任何主机查询隔离。 这些措施允许重试或其他恢复程序对主机和执行应用程序透明化。 这样可以避免错误，错误或消除过早的声明，从而导致主机应用程序中止和其他灾难性措施。 如果检测到的异常在分配的时间内没有解决，则可以调用其他数据恢复过程，包括设备复位，报告给主机的状态，以及处理的下一个请求。

    Photoreactive system and methods for prophylactic treatment of atherosclerosis
    5.
    发明授权
    Photoreactive system and methods for prophylactic treatment of atherosclerosis 有权
    光反应性体系及预防动脉粥样硬化的方法

    公开(公告)号：US08097028B2

    公开(公告)日：2012-01-17

    申请号：US11357358

    申请日：2006-02-17

    申请人： James C. Chen ,  Nicholas Yeo ,  Phillip Burwell ,  Thomas Wenger

    发明人： James C. Chen ,  Nicholas Yeo ,  Phillip Burwell ,  Thomas Wenger

    IPC分类号： A61N5/06

    CPC分类号： A61K41/0071 ,  A61N5/0601 ,  A61N5/062 ,  A61N2005/0602 ,  A61N2005/0651 ,  A61N2005/0661

    摘要： The present invention provides a prophylactic light activated treatment method for subjects at risk of a plaque-mediated thrombotic event, such as acute coronary syndromes. In one embodiment, the subject receives a dose of photosensitizer sufficient to result in a concentration of photosensitizer in the neovascularization associated with atherosclerotic disease to permit effective photodynamic therapy. Light of a wavelength that excites the photosensitizer, but that does not to any significant extent penetrate to an adventitial layer of the blood vessel, is applied to the region of the blood vessel. The therapeutic light dose, which may be applied in sequential stages, is sufficient to cause closure of neovasculature leakage and lead to plaque stabilization and reduced adverse clinical outcomes. The present invention further provides light transmission devices and systems useful in carrying out the methods of the present invention.

    摘要翻译： 本发明为患有斑块介导的血栓形成事件风险的受试者，例如急性冠状动脉综合征提供预防性光活化治疗方法。 在一个实施方案中，受试者接受足以导致与动脉粥样硬化疾病相关的新血管形成中的光敏剂浓度以允许有效的光动力疗法的剂量的光敏剂。 激发光敏剂的波长的光被施加到血管的区域，而不是任何显着程度的透射到血管的外膜层。 可以按顺序施用的治疗光剂量足以引起新血管渗漏的闭合并导致斑块稳定化并减少不良临床结果。 本发明还提供了用于实施本发明的方法的光传输装置和系统。

    IMMUNE SYSTEM STIMULATION BY LIGHT THERAPY INDUCED APOPTOTIC CELL DEATH IN ABNORMAL TISSUE
    6.
    发明申请
    IMMUNE SYSTEM STIMULATION BY LIGHT THERAPY INDUCED APOPTOTIC CELL DEATH IN ABNORMAL TISSUE 审中-公开
    轻度治疗诱导的免疫系统诱发异常细胞死亡的异常组织

    公开(公告)号：US20110009464A1

    公开(公告)日：2011-01-13

    申请号：US12817068

    申请日：2010-06-16

    申请人： James C. Chen

    发明人： James C. Chen

    IPC分类号： A61K31/407 ,  A61P35/00

    CPC分类号： A61K41/0057 ,  A61K9/0019 ,  A61K31/407

    摘要： The efficacy of light activated therapy treatment is enhanced by stimulating the immune system of the patient substantially above the pre-therapy level. Abnormal tissue that is destroyed by the light activated therapy releases factors that stimulate the immune system, leading to systemic reductions in abnormal tissue (i.e., reduction beyond the area treated using light), so long as the light therapy conditions favor apoptosis over necrosis. The volume of abnormal tissue destroyed is maximized to the extent possible, reducing tumor load, which reduces an amount of immunosuppressive factors in the body, enabling stimulation of the immune system to be successful.

    摘要翻译： 通过刺激患者的免疫系统显着高于治疗前水平，提高了光活化治疗的疗效。 被光激活治疗破坏的异常组织释放刺激免疫系统的因素，导致异常组织的系统性减少（即，除了使用光治疗的区域之外减少），只要光疗条件有利于凋亡超过坏死。 破坏的异常组织的体积尽可能地最大化，减少肿瘤负荷，这减少了身体中的免疫抑制因子的量，使得能够刺激免疫系统成功。

    ENHANCEMENT OF LIGHT ACTIVATED DRUG THERAPY THROUGH COMBINATION WITH OTHER THERAPEUTIC AGENTS
    7.
    发明申请
    ENHANCEMENT OF LIGHT ACTIVATED DRUG THERAPY THROUGH COMBINATION WITH OTHER THERAPEUTIC AGENTS 审中-公开
    通过与其他治疗药物组合来增强光活化药物治疗

    公开(公告)号：US20110008372A1

    公开(公告)日：2011-01-13

    申请号：US12832494

    申请日：2010-07-08

    申请人： James C. Chen

    发明人： James C. Chen

    IPC分类号： A61K39/395 ,  A61K31/58 ,  A61K31/395 ,  A61K31/69 ,  A61K31/165 ,  A61K31/704 ,  A61P35/00

    CPC分类号： A61K31/165 ,  A61K31/395 ,  A61K31/58 ,  A61K31/69 ,  A61K31/704

    摘要： The efficacy of light activated therapy treatment is enhanced by use of additional therapeutic agents. Abnormal tissue is destroyed by light activated therapy, and the associated administration of one or more additional therapeutic agents can synergistically enhance the therapy. For example, the concepts disclosed herein encompass the use of the following agents in combination with light activated drug therapy: (1) agents that selectively inhibit heat shock protein 90 (Hsp90); (2) agents that inhibit the Hedgehog pathway (which is believed to play a central role in allowing the proliferation and survival of certain cancer-causing cells, and which is implicated in many of the most deadly cancers); and, (3) agents for reducing the anti-apoptotic effects of Bcl-2 or Bcl-xL. These agents can be used with light activated drug therapy individually, or in various combinations and permutations.

    摘要翻译： 通过使用额外的治疗剂来增强光活化治疗的疗效。 异常组织被光激活治疗破坏，并且相关的一种或多种另外的治疗剂的施用可以协同增强治疗。 例如，本文公开的概念包括以下试剂与光活化药物治疗的组合的用途：（1）选择性抑制热休克蛋白90（Hsp90）的药剂; （2）抑制Hedgehog途径的药物（被认为在允许某些致癌细胞的增殖和存活中发挥核心作用，并且涉及许多致命的癌症）; 和（3）降低Bcl-2或Bcl-xL的抗凋亡作用的药剂。 这些药物可以单独使用轻度活化药物治疗，或以各种组合和排列使用。

    Integrated flat antenna and radio frequency unit for point-to-point microwave radios
    8.
    发明授权
    Integrated flat antenna and radio frequency unit for point-to-point microwave radios 失效
    集成平面天线和射频单元，用于点对点微波无线电

    公开(公告)号：US06396443B1

    公开(公告)日：2002-05-28

    申请号：US08665755

    申请日：1996-06-18

    申请人： Kenneth F. Conklin ,  David B. Giguere ,  James C. Chen

    发明人： Kenneth F. Conklin ,  David B. Giguere ,  James C. Chen

    IPC分类号： H01Q124

    CPC分类号： H01Q1/22 ,  H01Q13/28 ,  H01Q21/061 ,  H01Q23/00

    摘要： A point-to-point radio frequency unit/antenna has a flat antenna, preferably a continuous transverse stub antenna, integrated into the housing of the microwave unit. The radio frequency unit/antenna includes a housing having an exterior wall, a microwave radio frequency transceiver electronics package within the housing and having an antenna connection, and a flat antenna affixed to one face of the exterior wall of the housing. A microwave radio frequency feed communicates between the flat antenna and the antenna connection of the microwave transceiver electronics package. There is preferably a bracket structure on another face of the housing to affix the housing to a support.

    摘要翻译： 点对点射频单元/天线具有集成到微波单元的壳体中的平坦天线，优选地是连续的横向短截线天线。 射频单元/天线包括具有外壁的外壳，壳体内的微波射频收发器电子封装，并且具有天线连接，以及固定到外壳的外壁的一个面上的平坦天线。 微波射频馈送在平坦天线和微波收发器电子封装的天线连接之间进行通信。 在壳体的另一个表面上优选地具有支架结构，以将壳体固定到支撑件上。

    Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue
    9.
    发明授权
    Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue 失效
    使用与抗体缀合的聚乙二醇化光敏剂治疗异常组织

    公开(公告)号：US06344050B1

    公开(公告)日：2002-02-05

    申请号：US09218336

    申请日：1998-12-21

    申请人： James C. Chen

    发明人： James C. Chen

    IPC分类号： A61N700

    CPC分类号： A61K41/0057 ,  A61K47/60 ,  A61K47/68 ,  A61K47/6927

    摘要： A photosensitizer suitable for use in administering photodynamic therapy (PDT), conjugated with antibodies that are targeted to antigens on abnormal tissue and polyethylene glycol (PEG) or other polymer that extends the residence time of the conjugate within a patient's body. The resulting pegylated targeted conjugate is administered to a patient, and after the antibodies have had sufficient time to bind with the antigens, light from an external or internal source having a waveband corresponding to an absorption waveband of the photosensitizer is administered. Use of an external light source that emits relatively long wavelength light enables the light to pass through any intervening dermal layer and normal tissue between the external light source and the treatment site. Since the photosensitizer in the conjugate is bound to the abnormal tissue, the light therapy has minimal effect on the intervening normal tissue. Furthermore, the efficacy of the PDT is enhanced due to the increased concentration of the photosensitizer of the conjugate linked to the abnormal tissue.

    摘要翻译： 适用于施用光动力疗法（PDT）的光敏剂，其与针对异常组织上的抗原的抗体和聚乙二醇（PEG）或其它聚合物结合，所述聚合物延长缀合物在患者体内的停留时间。 将所得的聚乙二醇化靶向缀合物施用于患者，并且在抗体具有足够的时间与抗原结合之后，施用来自具有对应于光敏剂的吸收波段的波段的外部或内部源的光。 使用发射相对较长波长的光的外部光源使得光能够通过外部光源和处理部位之间的任何中间真皮层和正常组织。 由于缀合物中的光敏剂与异常组织结合，光疗对中间正常组织的影响最小。 此外，由于与异常组织连接的缀合物的光敏剂的浓度增加，PDT的功效增强。